NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,787.84 mln
Float48.61 mln
Earnings Date05/20/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
54.67
Transformational upside
Relative Strength
33
/ 100
Underperforming
Debt / Equity
0.05
Debt-free
ROE
-68.41
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Capricor Therapeutics is a US-based medical research company focused on developing new treatments for Duchenne muscular dystrophy and other serious conditions that currently lack effective therapies. Its most advanced treatment, Deramiocel, is currently in a Phase 3 clinical trial for Duchenne muscular dystrophy, while several other candidates based on engineered exosome technology are in earlier stages of testing for a range of diseases including COVID-19. The company holds licensing agreements with leading institutions such as Johns Hopkins University and Cedars-Sinai Medical Center to support its research and product development. Founded in 2005 and headquartered in San Diego, California, Capricor continues to build on these partnerships to bring novel therapies to patients.
